Altimmune, Inc. (NASDAQ:ALT) Short Interest Update

Altimmune, Inc. (NASDAQ:ALT) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 23,320,000 shares, a decrease of 5.2% from the January 15th total of 24,590,000 shares. Based on an average daily volume of 3,190,000 shares, the short-interest ratio is presently 7.3 days.

Analysts Set New Price Targets

A number of research analysts have recently commented on ALT shares. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Altimmune in a report on Wednesday, February 5th. Stifel Nicolaus started coverage on Altimmune in a report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price objective on the stock. Finally, UBS Group started coverage on Altimmune in a report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective on the stock. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $20.83.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Larson Financial Group LLC bought a new stake in shares of Altimmune in the third quarter valued at about $31,000. SBI Securities Co. Ltd. bought a new stake in Altimmune during the fourth quarter worth about $45,000. Virtus ETF Advisers LLC bought a new stake in Altimmune during the fourth quarter worth about $60,000. Cullen Frost Bankers Inc. bought a new stake in Altimmune during the fourth quarter worth about $72,000. Finally, Sunbelt Securities Inc. raised its holdings in Altimmune by 356.8% during the fourth quarter. Sunbelt Securities Inc. now owns 10,844 shares of the company’s stock worth $79,000 after acquiring an additional 8,470 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors.

Altimmune Stock Performance

NASDAQ ALT opened at $6.78 on Thursday. The stock has a fifty day moving average of $7.15 and a 200-day moving average of $7.18. The stock has a market capitalization of $482.19 million, a P/E ratio of -4.37 and a beta of 0.19. Altimmune has a 52 week low of $5.28 and a 52 week high of $14.84.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.